Overcoming Barriers to Guideline Adherence and IPE Adoption

Overview

This engaging, interactive presentation by 2 senior faculty will keep you up to date on EPA and EPA/DHA omega-3 fatty acids in ASCVD, how icosapent ethyl, approved for ASCVD-event reduction in patients with elevated triglycerides, may be used in your practice and in ASCVD primary and secondary prevention clinics nationwide.

Learning Objectives

• Explain why escalation of therapy beyond statins with nonstatin therapies is beneficial to reduce ASCVD risk
• Discuss recent data of omega-3 fatty acids and how these data may translate into clinical practice to reduce ASCVD events
• Apply professional society recommendations and expert opinion on a case-by-case basis for patients with or at high risk of ASCVD or at risk of further CV events